Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COPIKTRA vs ALIQOPA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.
ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.
Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies,Relapsed or refractory follicular lymphoma after at least two prior systemic therapies
Relapsed follicular lymphoma (FDA accelerated approval) in patients who have received at least two prior systemic therapies,Off-label: Other B-cell malignancies (e.g., diffuse large B-cell lymphoma, chronic lymphocytic leukemia)
25 mg orally twice daily
60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 7–10 hours in patients with relapsed or refractory CLL/SLL. Steady-state is achieved within 3–5 days of twice-daily dosing.
Terminal elimination half-life of approximately 39 hours in patients with hematologic malignancies; supports twice-daily dosing.
Primarily metabolized by CYP3A4; also involves CYP3A5 and UDP-glucuronosyltransferases (UGTs).
Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp).
Primarily via fecal excretion (approximately 70% of total dose) as unchanged drug and metabolites, with renal excretion accounting for <15% of the dose.
Primarily fecal (88%) and renal (8%) as unchanged drug and metabolites; biliary excretion contributes significantly.
~84% bound to plasma proteins, primarily to albumin.
84% bound to human plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Mean apparent volume of distribution (Vz/F) is approximately 100–150 L (or ~1.4–2.1 L/kg based on typical body weight), indicating extensive tissue distribution.
Apparent volume of distribution approximately 217 L in patients, indicating extensive extravascular distribution.
Oral bioavailability is approximately 22% following a 25 mg capsule under fasting conditions. Absorption is increased with high-fat meals; therefore, it should be taken on an empty stomach.
Oral bioavailability approximately 34% under fasted conditions; food increases exposure (AUC) by 34% but decreases Cmax by 11%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min).
For GFR ≥ 30 m L/min: no adjustment. For GFR < 30 m L/min: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild (Child-Pugh class A) or moderate (Child-Pugh class B), reduce dose to 25 mg once daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce to 40 mg; Child-Pugh C: avoid use.
Safety and efficacy in pediatric patients have not been established.
Safety and efficacy not established; no recommended dose.
No specific dose adjustment recommended for elderly patients, but monitor for adverse effects due to potential age-related renal or hepatic impairment.
No specific dose adjustment; monitor for increased toxicity due to age-related renal impairment.
WARNING: FATAL AND SERIOUS TOXICITIES: Fatal and serious toxicities including infections, diarrhea or colitis, cutaneous reactions, and pneumonitis have occurred with COPIKTRA.
Fatal and serious toxicities including infections, hyperglycemia, hypertension, non-infectious pneumonitis, and severe cutaneous reactions have occurred.
Fatal and serious infections,Fatal and serious diarrhea or colitis,Fatal and serious cutaneous reactions,Fatal and serious pneumonitis,Neutropenia,Hepatotoxicity,Embryo-fetal toxicity
Monitor for infections; manage hyperglycemia and hypertension; monitor for pneumonitis symptoms; avoid in patients with severe hepatic impairment.
Concurrent use with strong CYP3A inhibitors due to increased toxicity risk
None known, but caution in patients with severe hepatic impairment (Child-Pugh C) and those with active serious infections.
Avoid grapefruit and grapefruit juice; may increase dupilumab exposure. Take with or without food.
Avoid grapefruit, grapefruit juice, and Seville oranges as they may increase drug exposure. No other specific food interactions reported.
COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studies, duvelisib was embryotoxic and fetotoxic at maternal exposures below the recommended human dose. There are no adequate human data. Risks include embryo-fetal mortality, structural abnormalities, and growth impairment across all trimesters.
ALIQOPA (copanlisib) is a PI3K inhibitor. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, copanlisib was teratogenic and embryotoxic at maternal exposures below the recommended human dose. First trimester: High risk of structural anomalies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios; potential for fetal PI3K pathway disruption. Advise women of childbearing potential to use effective contraception during treatment and for at least 1 month after the last dose.
No data on duvelisib presence in human milk, effects on breastfed infant, or milk production. Due to potential for serious adverse reactions (e.g., immunosuppression, neutropenia), advise women not to breastfeed during treatment and for at least 1 month after last dose. M/P ratio unknown.
No data on the presence of copanlisib in human milk, its effects on the breastfed child, or on milk production. Due to the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 1 month after the last dose. M/P ratio: unknown.
No pharmacokinetic studies have been conducted in pregnant women. No dosing adjustments are recommended because duvelisib is contraindicated in pregnancy. If used inadvertently, the standard dose (25 mg twice daily) should be maintained until drug discontinuation is considered.
No specific dosing adjustments for pregnancy are established. The physiological changes of pregnancy (e.g., increased plasma volume, altered hepatic metabolism) may affect copanlisib pharmacokinetics, but data are lacking. Use during pregnancy should be avoided unless the potential benefit outweighs the risk. If treatment is necessary, consider therapeutic drug monitoring if available, and monitor for toxicity.
Monitor for hepatotoxicity with baseline and periodic liver function tests; avoid live vaccines; consider dose reduction in patients with moderate hepatic impairment (Child-Pugh B); watch for infections due to neutropenia; contraindicated in severe hepatic impairment (Child-Pugh C).
ALIQOPA (copanlisib) is a PI3K inhibitor with significant toxicity including hyperglycemia, hypertension, and infections. Monitor blood glucose and blood pressure closely during infusion. Premedicate with antihistamines and corticosteroids to reduce infusion-related reactions. Consider Pneumocystis jirovecii pneumonia prophylaxis due to immunosuppression.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection (fever, chills, cough) or jaundice (yellowing skin/eyes) immediately.,Use effective contraception during treatment and for at least 1 month after the last dose.,Do not receive live vaccines during or shortly after treatment.
Report any signs of infection (fever, cough, burning urination) immediately.,Monitor blood sugar levels regularly as this drug can cause high blood sugar.,Check blood pressure at home and report elevations.,Avoid grapefruit and Seville oranges during treatment.,Use effective contraception during treatment and for 1 month after last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COPIKTRA vs ALIQOPA, answered by our medical review team.
COPIKTRA is a PI3K Inhibitor Antineoplastic that works by Selective phosphoinositide 3-kinase (PI3K) delta and gamma inhibitor. Blocks PI3K signaling, reducing proliferation and survival of malignant B cells and T cells, and inhibits chemotaxis and adhesion of these cells.. ALIQOPA is a PI3K Inhibitor Antineoplastic that works by ALIQOPA (copanlisib) is a phosphatidylinositol 3-kinase (PI3K) inhibitor with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms. It induces apoptosis and inhibits proliferation in malignant B-cell lines.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COPIKTRA and ALIQOPA depend on the specific clinical indication. These are both PI3K Inhibitor Antineoplastic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COPIKTRA is: 25 mg orally twice daily. The standard adult dose of ALIQOPA is: 60 mg intravenously over 1 hour on days 1, 8, and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COPIKTRA and ALIQOPA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COPIKTRA is classified as Category C. COPIKTRA (duvelisib) is contraindicated in pregnancy. Based on its mechanism of action as a PI3K inhibitor and animal studies, it can cause fetal harm. In animal reproduction studi. ALIQOPA is classified as Category C. ALIQOPA (copanlisib) is a PI3K inhibitor. Based on its mechanism of action and animal studies, it can cause fetal harm when administered to a pregnant woman. There are no adequate . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.